Elimination of Mother-to-Child Transmission of HIV: The Final Frontier?
Karen Palmore Beckerman, MD
Professor of Pediatrics and Epidemiology, College of Physicians & Surgeons
Senior Research Director, ICAP at Columbia, Mailman School of Public Health
Columbia University, New York, NY
Videos of live meetings of PRN in NYC are owned and published by Physicians’ Research Network, Inc.
Copyright © 2018. All rights reserved.
Karen Palmore Beckerman has been working in the Bronx for the past twelve years caring for pregnant women with HIV and AIDS, as Director of High Risk Obstetrics at Bronx Lebanon Hospital Center and also as medical director of the Positive Perinatal Health Program in the hospital’s Center for Comprehensive Care. From 1994-2001 she was the Director of the Bay Area Perinatal AIDS Center at San Francisco General Hospital. In 1998, at the International AIDS Society Congress in Geneva, she and her team were the first to report the absence of mother to child transmission among 52 women living with HIV and AIDS who were monitored with viral load testing and treated with protease inhibitors during pregnancy. Dr Beckerman has been a member of the Antiretroviral Pregnancy Registry since 1999 and the Editorial Board of JAIDS and other journals, as well as review panels and data safety monitoring boards at the National Institutes of Health. She has lectured widely on preconception care, use of medications in pregnancy, and the safety and benefits of maternal antiretroviral therapy.
At the completion of this educational session, learners will:
- Know the weak points in current strategies to prevent pediatric AIDS.
- Be able to identify women at risk of acquiring HIV during the third trimester and breastfeeding.
- Understand the indications, risks and benefits of pre & post-exposure HIV transmission prophylaxis before, during and after pregnancy.
- Appreciate the importance of Family Planning and planning a family among HIV-affected couples in both resource-rich and resource-constrained
settings.
This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; and Merck & Co.
